Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ELDN Eledon Pharmaceuticals, Inc.

Trading 02-18 13:47:44 EST

2.14

+0.03

+1.42%

High2.20	Low2.11	Vol271.32K
Open2.12	D1 Closing2.11	Amplitude4.27%
Mkt Cap160.57M	Tradable Cap160.48M	Total Shares75.03M
T/O585.85K	T/O Rate0.36%	Tradable Shares74.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ELDN","market":"US","secType":"STK","nameCN":"Eledon Pharmaceuticals, Inc.","latestPrice":2.14,"timestamp":1771440363779,"preClose":2.11,"halted":0,"volume":271315,"delay":0,"changeRate":0.014218009478673105,"floatShares":74988604,"shares":75034300,"eps":-1.097551,"marketStatus":"Trading","change":0.03,"latestTime":"02-18 13:47:44 EST","open":2.12,"high":2.195,"low":2.105,"amount":585845.324515,"amplitude":0.042654,"askPrice":2.14,"askSize":708,"bidPrice":2.13,"bidSize":703,"shortable":3,"etf":0,"ttmEps":-1.097551,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771448400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":2.11,"preHourTrading":{"tag":"盘前","latestPrice":2.1101,"preClose":2.11,"latestTime":"08:50 EST","volume":419,"amount":889.3601819999999,"timestamp":1771422636370,"change":0.0001,"changeRate":0.000047,"amplitude":0.007062},"postHourTrading":{"tag":"盘后","latestPrice":2.1198,"preClose":2.11,"latestTime":"18:52 EST","volume":10671,"amount":22565.24,"timestamp":1771372361571,"change":0.0098,"changeRate":0.004645,"amplitude":0.004645},"volumeRatio":0.72013,"impliedVol":0.3381,"impliedVolPercentile":0.1434},"requestUrl":"/m/hq/s/ELDN/wiki","defaultTab":"wiki","newsList":[{"id":"2606291151","title":"Eledon Pharmaceuticals Reports Positive 24-Month Phase 1b Data for Tegoprubart in Kidney Transplant Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2606291151","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606291151?lang=en_us&edition=fundamental","pubTime":"2026-01-26 14:51","pubTimestamp":1769410295,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Inc. announced it will present 24-month follow-up data from eight patients enrolled in the Phase 1b long-term extension trial evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, scheduled for January 23-25, 2026, in Scottsdale, Arizona. The results indicate no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation during the study period. Mean estimated glomerular filtration rate  increased from 67.0 mL/min/1.73 m at 12 months to 74.2 mL/min/1.73 m at 24 months. Following the presentation, a copy of the poster will be available on the company’s website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL1mmDgn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD","SG9999014005.SGD","ELDN","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","SG9999014039.USD","BK4585","SG9999014021.USD","LU2210149790.SGD","BK4112","SG9999014013.SGD","BK4588"],"gpt_icon":0},{"id":"2605409396","title":"Analysts Conflicted on These Healthcare Names: Ufp Technologies (UFPT), Eledon Pharmaceuticals (ELDN) and CareDx (CDNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605409396","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605409396?lang=en_us&edition=fundamental","pubTime":"2026-01-23 22:50","pubTimestamp":1769179817,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ufp Technologies (UFPT – Research Report), Eledon ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-ufp-technologies-ufpt-eledon-pharmaceuticals-eldn-and-caredx-cdna-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-ufp-technologies-ufpt-eledon-pharmaceuticals-eldn-and-caredx-cdna-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CDNA","BK4581","BK4137","ELDN","LU0029874061.USD","BK4136","BK4585","LU0128526141.USD","HCSG","UFPT","XBI","BK4139","LABU","BK4198","XLV","BK4588"],"gpt_icon":0},{"id":"2602180613","title":"Eledon Pharmaceuticals Inc - Funds Expected to Support Operations Into 2Q 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2602180613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602180613?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:05","pubTimestamp":1767906303,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA3MPSSQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELDN"],"gpt_icon":0},{"id":"2602313983","title":"Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602313983","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602313983?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:05","pubTimestamp":1767906300,"startTime":"0","endTime":"0","summary":"Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive prelimi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215790/0/en/Eledon-Pharmaceuticals-Highlights-Recent-Business-Milestones-and-Provides-2026-Outlook.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4089","IE0009354923.USD","ELDN"],"gpt_icon":0},{"id":"2600093533","title":"Eledon Pharmaceuticals Swaps Shares for Pre-Funded Warrants in Private Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2600093533","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600093533?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:31","pubTimestamp":1767389469,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Inc. announced it has entered into an exchange agreement with Coastlands Capital Partners LP, under which Coastlands exchanged 4,203,764 shares of Eledon’s common stock for a pre-funded warrant to purchase the same number of shares. The warrant is exercisable immediately at an initial exercise price of $0.001 per share, subject to certain adjustments, and includes beneficial ownership limitations to prevent the holder from exceeding specified ownership thresholds. The transaction was completed without registration under the Securities Act of 1933, relying on the exemption provided by Section 3.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to genera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDLJ6f5F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"gpt_icon":0},{"id":"2588724707","title":"Eledon Pharmaceuticals CEO to Join Fireside Chat at Piper Sandler Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724707","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724707?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:01","pubTimestamp":1764590460,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Inc. will participate in the 37th Annual Piper Sandler Healthcare Conference, with CEO David-Alexandre C. Gros, M.D., joining a fireside chat on Thursday, December 4, 2025, at 8:50 a.m. ET. A webcast replay of the session will be available on the company's website following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL5hfsNs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","LU0314104364.USD","BK4139","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","PIPR","BK4127","NDAQ","BK4588","ELDN","IE00B64PRP62.GBP","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2584969200","title":"Eledon Pharmaceuticals Shares Rise About 10% to $1.69 in Active Trading Volume After the Bell Following Preliminary Update on Drug Test in Diabetes Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2584969200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584969200?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:18","pubTimestamp":1763504314,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nL6N3WU198:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELDN"],"gpt_icon":0},{"id":"2584163966","title":"BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant","url":"https://stock-news.laohu8.com/highlight/detail?id=2584163966","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584163966?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:36","pubTimestamp":1763501761,"startTime":"0","endTime":"0","summary":"BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant Nov 18 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O:ELEDON RE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUABCHBNC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"gpt_icon":0},{"id":"2584965919","title":"Eledon Pharmaceuticals Reports Promising Early Results for Tegoprubart in Islet Transplant Trial for Type 1 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2584965919","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584965919?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:05","pubTimestamp":1763499927,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Inc. has announced preliminary results from an ongoing investigator-initiated clinical trial evaluating tegoprubart, an investigational anti-CD40 Ligand  antibody, as the core immunosuppressant in islet transplantation for individuals with type 1 diabetes. The trial, conducted at the University of Chicago Medicine's Transplant Institute, is assessing a tacrolimus-free immunosuppression regimen to prevent islet transplant rejection. Preliminary data from the first six patients were presented at the Rachmiel Levine-Arthur Riggs Diabetes Research Symposium, held November 14-17, 2025, at City of Hope in Los Angeles, California. All six subjects in the preliminary cohort achieved insulin independence. The study is funded by Breakthrough T1D, which has also committed to support further research on tegoprubart in this context.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL6MvGDw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","BK4139","ELDN","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BKPKM429.USD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2584965695","title":"Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at Uchicago Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2584965695","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584965695?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:05","pubTimestamp":1763499900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUABCHBNC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELDN"],"gpt_icon":0},{"id":"2584965619","title":"Eledon Pharmaceuticals Inc - Tegoprubart Well Tolerated, No Serious Infections or Rejection Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2584965619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584965619?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:05","pubTimestamp":1763499900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUABCHBNC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELDN"],"gpt_icon":0},{"id":"2584495309","title":"Eledon Pharmaceuticals Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2584495309","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584495309?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:20","pubTimestamp":1763475600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ELDN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 09:20 ET (14:20 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"gpt_icon":0},{"id":"2584931996","title":"Eledon Pharmaceuticals price target lowered to $8 from $9 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2584931996","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584931996?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:35","pubTimestamp":1763465708,"startTime":"0","endTime":"0","summary":"Guggenheim lowered the firm’s price target on Eledon Pharmaceuticals (ELDN) to $8 from $9 and keeps a Buy rating on the shares following the Q3 rep...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eledon-pharmaceuticals-price-target-lowered-to-8-from-9-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eledon-pharmaceuticals-price-target-lowered-to-8-from-9-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELDN","BK4139"],"gpt_icon":0},{"id":"2583682023","title":"Eledon Pharma Q3 EPS $(0.21) Beats $(0.24) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682023","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682023?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:05","pubTimestamp":1763157943,"startTime":"0","endTime":"0","summary":"Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 11.39 percent. This is a 25 percent increase over losses of $(0.28) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48882635/eledon-pharma-q3-eps-0-21-beats-0-24-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSYW.SI","USAW.SI","TQQQ","USJW.SI","QLD","QID","NQmain","ELDN","BK4139","NVIW.SI","PSQ","SQQQ",".IXIC","MNQmain"],"gpt_icon":0},{"id":"2583827186","title":"Eledon Pharmaceuticals posts Q3 net loss of $17.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583827186","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583827186?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:00","pubTimestamp":1763157622,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals reported a net loss of $17.5 million, or $0.21 per basic common share, for the third quarter of 2025, compared to a net income of $77.0 million, or $1.05 per basic common share, in the same period in 2024. The 2024 net income included a non-cash gain of $96.4 million from changes in warrant liabilities; without this gain, the net loss would have been $19.5 million. As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $93.4 million, down from $140.2 million at the end of 2024. Research and development expenses were $15.0 million, compared to $16.5 million in the third quarter of 2024. General and administrative expenses were $4.1 million, similar to $4.0 million in the prior year. Business highlights include positive Phase 2 BESTOW trial results for tegoprubart, supporting advancement to Phase 3 for kidney transplant rejection prevention, and a $57.5 million financing to fund transplantation programs.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL3Yzz7v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","BK4139","IE00BKPKM429.USD","BK4585","BK4112"],"gpt_icon":0},{"id":"2583734682","title":"Eledon Pharmaceuticals Q3 Operating Expenses USD 19.07 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583734682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583734682?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:00","pubTimestamp":1763157601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX0F274D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELDN","BK4139"],"gpt_icon":0},{"id":"2583268273","title":"Eledon Pharmaceuticals Q3 Income From Operations USD -19.07 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583268273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583268273?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:00","pubTimestamp":1763157601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX0F274D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELDN"],"gpt_icon":0},{"id":"2583682035","title":"Press Release: Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682035","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682035?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:00","pubTimestamp":1763157600,"startTime":"0","endTime":"0","summary":"Data supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection. Strengthened balance sheet with $57.5 million financing to advance transplantation programs. IRVINE, Calif., Nov. 14, 2025  -- Eledon Pharmaceuticals, Inc.   today reported its third quarter 2025 operating and financial results and reviewed recent business highlights.-- Presented results from the Phase 2 BESTOW trial evaluating tegoprubart. for the prevention of organ rejection in patients receiving a kidney. transplant at the American Society of Nephrology's Kidney Week 2025. Annual Meeting in Houston, TX. Tegoprubart demonstrated a favorable. safety and tolerability profile, substantially reducing the metabolic,tacrolimus. Kidney function, as measured by estimated glomerular. filtration rate , was approximately 69 mL/min/1.732 at 12-months. -- Based on the Phase 2 BESTOW results, Eledon plans to advance tegoprubart. into Phase 3 development following discu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"gpt_icon":0},{"id":"2583682607","title":"Top News Today: Stocks Mixed as AI Selloff Slows","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682607?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:45","pubTimestamp":1763156700,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields rose amid doubts about the Federal Reserve's next move.COMMODITIES: Oil futures rose after Ukraine drone attacks on a Russian Black Sea port.Walmart picked one of its longtime executives, John Furner, to become its next chief executive, preserving its tradition of promoting an insider to steer the nation's biggest retailer. The 51-year-old Furner was seen inside the company as the likely heir apparent and ready for his next step after six years leading Walmart's U.S. business. Outside the company, the Walmart veteran-and son of a Walmart executive-was seen as a potential CEO candidate for other firms too.The reopened federal government will on Thursday release the first backlogged monthly jobs report, for the month of September. And a flood of other data is due to start flowing soon.They promised investments in the U.S. that would reduce Switzerland's trade imbalance with the U.S., according to people familiar wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRG","IE00B2B36J28.USD","STI","ALBT","GPUS","KALA","RHEP","LU0061474960.USD","XP","LFMD","LU0203347892.USD","JJSF","BK4007","LU2750360641.GBP","UAVS","HP","SPRB","PRPO","LU1430594728.SGD","LU1066053197.SGD","LU2468319806.SGD","BK4211","IIIV","IPAR","PNBK","NWBO","LU2430703178.SGD","BYFC","MRK","LU2430703251.USD","OTLC","BK4152","LU2023250843.SGD","LU1974910355.USD","TVGN","ARMK","LITS","ALTS","LWLG","LU2361044865.SGD","BK4561","BRC","LU0861579265.USD","LU2592432038.USD","ASPI","WMT","AAME","TORM","ELDN"],"gpt_icon":0},{"id":"2582374400","title":"Eledon Pharmaceuticals Shares Sink After Pricing $50M Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374400","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374400?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:45","pubTimestamp":1762955100,"startTime":"0","endTime":"0","summary":"Shares of Eledon Pharmaceuticals fell after the company priced a $50 million public offering of common stock and pre-funded warrants.The stock fell 17% to $1.77 in premarket trading Wednesday. Through Tuesday's close, shares have lost nearly half of their value in the past year.Ahead of the opening bell, the Irvine, Calif., biotech company said it will sell about 15.2 million shares of its common stock for $1.65 apiece. To certain investors, the company will instead sell pre-funded warrants immediately exercisable to purchase common stock.Eledon will also grant underwriters a 30-day option to purchase up to about 4.55 million shares of common stock at a discounted price.The company said it will use net proceeds from the sale to support the clinical development of its product candidates and advance its pipeline programs, as well as for general corporate purposes.Leerink Partners, Cantor and LifeSci Capital are acting as joint book-running managers for the offering, which is expected to ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eledon.com","stockEarnings":[{"period":"1week","weight":0.0096},{"period":"1month","weight":-0.0047},{"period":"3month","weight":0.3613},{"period":"6month","weight":-0.1758},{"period":"1year","weight":-0.5342},{"period":"ytd","weight":0.3974}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0127},{"period":"3month","weight":0.0305},{"period":"6month","weight":0.0744},{"period":"1year","weight":0.12},{"period":"ytd","weight":0.0014}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.166113},{"month":2,"riseRate":0.5,"avgChangeRate":-0.02019},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.064374},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.006649},{"month":5,"riseRate":0.545455,"avgChangeRate":0.811807},{"month":6,"riseRate":0.181818,"avgChangeRate":-0.182936},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.081289},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.035259},{"month":9,"riseRate":0.272727,"avgChangeRate":0.085532},{"month":10,"riseRate":0.5,"avgChangeRate":2.263696},{"month":11,"riseRate":0.5,"avgChangeRate":-0.069266},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.094259}],"exchange":"NASDAQ","name":"Eledon Pharmaceuticals, Inc.","nameEN":"Eledon Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eledon Pharmaceuticals, Inc.(ELDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eledon Pharmaceuticals, Inc.,ELDN,Eledon Pharmaceuticals, Inc.股票,Eledon Pharmaceuticals, Inc.股票老虎,Eledon Pharmaceuticals, Inc.股票老虎国际,Eledon Pharmaceuticals, Inc.行情,Eledon Pharmaceuticals, Inc.股票行情,Eledon Pharmaceuticals, Inc.股价,Eledon Pharmaceuticals, Inc.股市,Eledon Pharmaceuticals, Inc.股票价格,Eledon Pharmaceuticals, Inc.股票交易,Eledon Pharmaceuticals, Inc.股票购买,Eledon Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eledon Pharmaceuticals, Inc.(ELDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction